ERBB3 and head and neck squamous cell carcinoma: Our data suggest that HPV-negative SCCHN but not HPV-positive SCCHN may respond to cetuximab or duligotuzumab, though the addition of HER3 inhibition does not significantly improve response but may increase the frequency of select lower grade GI toxicities.